Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation	Melphalan hydrochloride (Cydex; CDX-353; Phelinun)	Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer	Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer	2021	View \| Download
Naxitamab in combination with granulocyte-macrophage colony stimulation factor for relapsed/refractory high-risk neuroblastoma	Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF; GM-CSF vaccine) , Naxitamab (Hu3F8; Danyelza)	Neuroblastoma	Neurological Cancer	2020	View \| Download
Eflornithine for treating neuroblastoma	Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate)	Dermatology , Neuroblastoma	Bone and Cartilage Cancer	2021	View \| Download
131I-omburtamab for neuroblastoma with central nervous system or leptomeningeal metastasis in paediatric patients	Omburtamab I-131 (131I-mu8H9)	Neuroblastoma	Neurological Cancer	2019	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications